SX-682 and Atezolizumab for the Treatment of Advanced or Metastatic, Recurrent Non-small Cell Lung Cancer
Status:
NOT_YET_RECRUITING
Trial end date:
2031-11-01
Target enrollment:
Participant gender:
Summary
This phase II trial tests how well SX-682 and atezolizumab works for the treatment of non-small cell lung cancer (NSCLC) that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or that has spread from where it first started (primary site) to other places in the body (metastatic), and has come back after a period of improvement (recurrent). SX-682 blocks proteins that may be able to stimulate the immune system to kill and eliminate tumor cells. Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Giving SX-682 and atezolizumab may be effective for the treatment of advanced or metastatic, recurrent NSCLC.
Phase:
PHASE2
Details
Lead Sponsor:
University of Washington
Collaborators:
Genentech, Inc. National Cancer Institute (NCI) Syntrix Biosystems, Inc.
Treatments:
atezolizumab Biopsy Magnetic Resonance Spectroscopy Specimen Handling